Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 10/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217918 | 0.88 | RAB9A (0.50) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL7406144 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL3172593 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL3172600 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL28836255 | 0.83 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL7367598 | 0.83 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| Hydrochloric Acid SCHEMBL27968384 | 0.83 | RAB9A (0.69) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| Hydrochloric Acid SCHEMBL28049456 | 0.83 | RAB9A (0.69) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL1976765 | 0.82 | POLB (0.50) | RAB9AALDH1A1SMN1; SMN2LMNAPEPD | |
| SCHEMBL30070875 | 0.81 | RAB9A (0.55) | RAB9AALDH1A1SMN1; SMN2ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | RAB9A 2417/4885ALDH1A1 570/4885SMN1; SMN2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.